BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
申请人:Xenon Pharmaceuticals Inc.
公开号:US20180162868A1
公开(公告)日:2018-06-14
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
Quinazoline derivatives and therapeutic use thereof
申请人:Lee B. Young
公开号:US20050187231A1
公开(公告)日:2005-08-25
Quinazoline derivatives represented by the general formula
pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also described.
Chiral Brønsted Acids Catalyze Asymmetric Additions to Substrates that Are Already Protonated: Highly Enantioselective Disulfonimide-Catalyzed Hantzsch Ester Reductions of NH–Imine Hydrochloride Salts
作者:Benjamin List、Vijay N. Wakchaure、Carla Obradors
DOI:10.1055/s-0040-1706413
日期:2020.10
are frequently used substrates in asymmetric Bronsted acid catalysis, their corresponding salts are generally considered unsuitable reaction partners. Such processes are challenging because they require the successful competition of a catalytic amount of a chiral anion with a stoichiometric amount of an achiral one. We now show that enantiopure disulfonimides enable the asymmetric reduction of N–H imine
Quinazoline Derivatives and Therapeutic Use Thereof
申请人:Lee Young B.
公开号:US20090030021A1
公开(公告)日:2009-01-29
Quinazoline derivatives represented by the general formula
pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also disclosed.